Phase 2/3 Study to Evaluate the Safety and Efficacy of TLC590 for Postsurgical Pain Management
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
A Phase 2/3 randomized, double-blind, 2-part, comparator- and placebo-controlled study to
assess the safety and efficacy of postsurgical local infiltration in adult subjects following
inguinal hernia repair surgery. In this study, 2 doses of a concentration of TLC590 24.5
mg/mL in inguinal hernia repair will be assessed in an initial Phase 2 part before proceeding
to a Phase 3 pivotal evaluation.